Novālent Launches Patented US Technology in Australia & New Zealand Markets to Help Fight COVID-19
GREENSBORO, N.C.--(BUSINESS WIRE)-- Novālent Biotech, Inc (‘Novālent’), a US biotechnology engineering firm, announces it is launching its patented surface disinfectant products in Australia and New Zealand.
Novālent technology protects against bacteria and viruses on surfaces for up to 90 days. The antimicrobial is applied to surfaces by wiping, spraying, or fogging. Once dry, the surface remains protected even if touched or recontaminated multiple times.
Even routine disinfecting does not diminish Novālent’s protective properties. The technology is based on a patented non-toxic monomolecular layer that provides up to 90 days of antimicrobial protection. Novālent products have applications across industries including buildings and facilities, food service, hospitality, fitness, healthcare, transport, and textiles and apparel.
“We’ve seen a rapid adoption of our technology in the US from market leaders including PepsiCo, Hanesbrands, and Pilgrim’s,” said Kevin Parrish, CEO of Novālent. “We are now bringing this technology to the Australia and New Zealand market to provide customers with a truly revolutionary product based on more than two decades of research by our R&D engineering team in the US.”
The Australian Therapeutic Goods Administration (TGA) has registered Novālent technology as an effective commercial-grade surface disinfectant against coronaviruses including the virus that causes COVID-19.
Novālent® is a leading U.S. biotechnology engineering firm which has pioneered the development of proprietary, long-lasting technology that protects against germs. Novālent® technology is based on a patented, non-toxic monomolecular layer that continuously inhibits the growth of bacteria for up to 90 days on surfaces. Used by leading US firms including PepsiCo, Pilgrims and HanesBrands, Novālent is private equity-backed and is headquartered in Greensboro, North Carolina, with five offices around the world. Visit www.novalent.com for more information.
Christine Pietryla Wetzler
Source: Novālent Biotech, Inc